FOSTER CITY, CA / ACCESSWIRE / October 10, 2016 / Aoxing Pharmaceutical Company, Inc. (NYSE MKT:AXN), a specialty pharmaceutical
company focusing on research, development, manufacturing, and distribution of narcotic, pain-management and addiction treatment
pharmaceuticals, today announced that its audited consolidated financial statements for the fiscal year ended June 30, 2016,
included in the Company's Annual Report on Form 10-K, which was filed on October 5, 2016 with the Securities and Exchange
Commission, contain an audit opinion from its independent registered public accounting firm that includes a going concern
qualification.
This announcement is made pursuant to NYSE MKT Company Guide Section 610(b), which requires separate disclosure of receipt of an
audit opinion containing a going concern qualification.
CONTACT:
Aoxing Pharmaceutical Company: 646-367-1747 investor.relations@aoxingpharma.com
SOURCE: Aoxing Pharmaceutical Company, Inc.
